Figure 3. Role of miR-130a in age-dependent impairment of endothelial cell angiogenic activities. (A) Graph showing serial passaging over time in HUVECs. An important reduction of cell proliferation is seen after 25 passages. Low-passage HUVECs (LP, 4-6 passages) were compared to high-passage HUVECs (HP, 28 passages or more) in the following experiments. (B–E) Evaluation of angiogenesis and cell migration in vitro using matrigel (B, D) and scratch (C, E) assays in LP or HP HUVECs treated with miR-130a mimic (miR-130a), anti-miR-130a (miR-130a inh), or a scrambled miR mimic control (miRCTL). Data are mean ± SEM (n=5/group). * p<0.05 vs. LP+miRCTL; # p<0.05 vs. HP+miRCTL. ▲ p<0.05 vs. LP+miRCTL. (F, G) Quantification of angiogenesis and cell migration in vitro using matrigel (F) and scratch (G) assays in MAECs isolated from young or old mice and treated with miR-130a mimic (miR-130a), anti-miR-130a (miR-130a inh), or a scrambled miR mimic control (miRCTL). Data are mean ± SEM (n=3/group). * p<0.05 vs. young+miRCTL; # p<0.05 vs. old+miRCTL. ▲ p<0.05 vs. young+miRCTL.